activation, 345
adhesion molecules, 345
age factor, 373
ageing, 30
allergic bronchopulmonary aspergillosis, 414
allergy, 6, 314
alveolar macrophage, 363
American tegumentary leishmaniasis, 338
animal models, 194
Anisakis simplex, 203
antigen fractions, 338
anti-tuberculous treatment, 329
anti-tumour mechanism, 216
apoptosis, 237
appendicectomy, 117
appendicitis, 117
asthma, 161, 249
atherosclerosis, 269
atherosclerotic plaque, 452
autoantibody, 167, 237, 572
autoantigen, 572
autoimmune disease, 110
autoimmunity, 1, 167, 237
β1-adrenergic receptor, 209
β-1,3-D-glucan, 65
B cell mitogenesis, 560
B lymphocyte subsets, 373
B lymphocytes, 30, 373
B16 F10 melanoma, 216
bacterial infection, 41
basophils/mast cells, 203
4-1BB, 228
BCR, 30
bronchial asthma with allergic rhinitis, 414
bronchiolitis, 513
Buruli disease, 445
cancer, 314
capsular polysaccharide, 543
cardiac function, 209
cardiomyopathy, 209
CD1-restricted, 194
CD4+ T-cell, 110
CD8 T cells, 398
CD28, 93
CD127, 398
CD137, 228
cell contact, 560
cellular immunity, 132
c-Jun N-terminal kinase (JNK), 24
classical complement, 15
coccidioidomycosis, 458
commensal bacteria, 474, 503
common variable immunodeficiency, 373
complement deficiency, 297
complement regulatory proteins, 297
complement, 274
conjugate vaccine, 132
contact allergy, 494
Crohn's disease, 125, 550
cryoglobulinaemia, 288
cytokine, 50, 85, 103, 161, 180, 338, 357, 363, 380, 435, 445
cytomegalovirus, 167
cytoplasmic domains, 572
cytotoxic T lymphocytes, 139
cytotoxicity, 345, 534
dendritic cells, 314, 329, 357, 550
dengue, 345
dextran, 103
diabetes, 194
differentiation antigens, 373
disease susceptibility/resistance/polymorphisms, 435
endothelial cells, 58, 523
environmental factors, 1
eosinophils, 161
epitope analysis, 572
ERK, 150
erythrocyte CR1, 274
experimental colitis, 228
experimentally induced gastric lesions, 24
factor I, 297
Fas ligand, 281
gangrenous, 117
gene expression profiling, 523
germ-free mice, 503
glatiramer acetate, 357
glycopeptides, 139
glycosylation, 139
GM-CSF, 260
Gram-negative bacteria, 404
granzyme B, 534
gut motility, 389
GW bodies, 572
HAART, 398
HCV-RNA, 288
heterogeneity, 523
HGE, 322
high-sensitive-C-reactive protein, 452
HIV, 435
HLA-B27, 474
HSP70, 550
human dendritic cells, 513
human granulocytic ehrlichiosis, 322
human, 132
hyperplasia, 110
hypersensitivity, 203
ICAM-1, 216
IFN-α production, 329
IgA, 65, 467
IgA subclass, 543
IL-6, 58, 85
IL-7, 398
IL-8, 58
IL-10, 281, 494
IL-12, 150
immune response, 380, 389
immunization, 209
immunoglobulin M, 41
immunomodulation, 85
immunopathology, 445
immunoregulation, 30, 494
infection, 389, 467
inflammation, 70, 269, 389
inflammatory mediators, 458
inhibition, 15
innate immunity, 41, 297, 420
interferon-gamma (IFN-γ), 117, 228, 467
interleukin-4, 228
interleukin-6, 125
interleukin-6 receptor, 452
interleukin-10 (IL-10), 117
interleukin-12, 322
interleukin-18, 41
intestinal macrophages, 484
intranasal, 467
Kawasaki disease, 427
Lactobacillus casei/ssp. casei, 103
larynx, 6
latent, 180
Leishmania amazonensis, 338
Leishmania braziliensis, 338
leptin, 452
leukaemia/lymphoma/myeloma, 78
lipid, 269
lipopolysaccharide, 58
liver ischaemia, 15
LPS, 484, 523
l-selectin, 216
lung cancer, 363
lungs, 467
Lyme disease, 322
lymphocytes, 357, 534
M-CSF, 260
M. tuberculosis, 329
macrophage, 260
mannan-binding lectin, 414
MD-2, 58
melanoma, 93
memory subset, 398
meningitis, 458
MHC/HLA, 435
mice, 237
microarray, 260
minor HC, 78
MMLC, 85
monocytes, 534
mouse, 93, 216
mRNA, 458
mucosal immunity, 503
multiple sclerosis (MS), 305, 357
myasthenia gravis, 110
Mycobacterium tuberculosis, 150, 180, 329
Mycobacterium ulcerans, 445
natural killer T cells (NKT cells), 194
natural killer, 103
neutrophils, 70, 404
NF-κB, 58
nickel, 494
NK cells, 345
nude, 474
oral tolerance, 503
oral, 65, 249
osteomyelitis, 404
OX40 (CD134), 110
pathogen-associated molecular patterns, 249
pathogenesis, 427
patients, 345
periodontitis, 50
peripheral blood lymphocytes, 288
phase I, 65
phenotype, 161, 363
phospholipids, 572
PI 3-K, 150
PI-9, 534
pig, 6
pneumococcal, 543
poly (ADP-ribose) polymerase, 281
polymorphism, 281, 404, 420
Porphyromonas gingivalis, 50
pp65 lower matrix protein, 167
primary immunodeficiency, 297
programmed cell death, 30
progressive, 180
prostaglandin, 50
proteases, 85
PsaA, 543
Pseudomonas aeruginosa, 132
RANTES, 58
rat model, 15
rats, 24, 203
reactive nitrogen intermediates, 560
receptor, 398, 420
recurrent infections, 297
reperfusion injury, 15
respiratory syncytial virus, 513
rheumatoid arthritis, 1
RT-PCR, 180
safety, 65
saliva, 543
sarcoidosis, 420
serological evidence, 427
signal joint T cell receptor excision circles (sjTRECs), 305
signal transduction molecules, 484
single nucleotide polymorphism, 414
SLE flare, 274
SLE nephritis, 274
smooth muscle, 389
soluble gp130, 125
soluble interleukin-6 receptor, 125
sputum cells, 161
Staphylococcus aureus, 70
studies of mice and rats, 194
superantigen, 427
suppressor macrophage, 560
suppressor mediators, 560
survival signals, 30
synbiotic, 103
systemic lupus erythematosus, 167, 281
T cell, 93, 474
T cell homeostasis, 305
T cell mitogenesis, 560
T cell proliferation, 380
T cell receptor (TCR), 78, 305
T lymphocyte subsets, 373
TB, 467
Th1/Th2 cytokines, 41
therapy/immunotherapy, 314
tick-borne, 322
TLR4, 58, 420
TNF-α, 150, 484, 550
tolerance, 237, 249
toll-like receptor 4, 58, 269, 404
toxin, 427
transdifferentiation, 70
transgenic rats, 474
transplant, 6
TruCOUNT, 329
tumour immunity, 139
ulcerative colitis, 125
vaccination, 380
vascular cell adhesion molecule-1, 452
vasculitis, 458
viraemic patients, 398
visceral leishmaniasis, 380
vitamin D, 58
whole blood model, 50